Top

Clinical and Translational Oncology

Published in:

01-02-2013 | Research Article

Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma

Authors: Liang Wang, Jun Yuan, Yanyang Tu, Xinggang Mao, Shiming He, Guoqiang Fu, Jianhai Zong, Yongsheng Zhang

Published in: Clinical and Translational Oncology | Issue 2/2013

Abstract

Aim

Matrix metalloproteinase (MMP)-14 and MMP-19 have been demonstrated to play an important role in the development of human gliomas. However, their prognostic values are not clear. The aim of this study was to investigate whether co-expression of MMP-14 and MMP-19 has prognostic relevance in human gliomas.

Methods

Immunohistochemistry and western blot were used to investigate the expression of MMP-14 and MMP-19 proteins in 128 patients with gliomas.

Results

The expression levels of MMP-14 and MMP-19 proteins in glioma tissues were both significantly higher (both P < 0.001) than those in non-neoplastic brain tissues according to the immunohistochemistry analysis, which was confirmed by the western blot analysis. Additionally, the overexpression of either MMP-14 or MMP-19 was significantly associated with the advanced WHO grade (both P = 0.02), the low Karnofsky performance score (KPS) (P = 0.008 and 0.01, respectively) and the poor overall survival (both P = 0.01). Moreover, the Multivariate Cox proportional-hazards regression analysis revealed that the increased expressions of MMP-14 and MMP-19 were both independent prognostic factors for poor overall survival (both P = 0.02). Furthermore, the co-expression of MMP-14 and MMP-19 was additively and more significantly (P = 0.006) associated with adverse prognosis in patients with gliomas than respective expression of MMP-14 and MMP-19.

Conclusions

These findings indicated for the first time that the co-expression of MMP-14 and MMP-19 is significantly correlated with prognosis in glioma patients, suggesting that the co-expression of these proteins may be used as both an early diagnostic and independent prognostic marker.

Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109:93PubMedCrossRef

Louis DN, Ohgaki H, Wiestler ODl (2007) The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 114:97–109PubMedCrossRef

Mu YG, Chen MZ, Chen ZP, Zhou WN, Zhang XH, Sai K (2004) Microsurgical technique of brain glioma—a report of 183 cases. Ai Zheng 23:1317–1321PubMed

O’Hara A, Lim FL, Mazzatti DJ, Trayhurn P (2009) Microarray analysis identifies matrix metalloproteinases (MMPs) as key genes whose expression is up-regulated in human adipocytes by macrophage-conditioned medium. Pflugers Arch 458:1103–1114PubMedCrossRef

Murphy G, Knäuper V, Cowell S, Hembry R, Stanton H, Butler G, Freije J, Pendás AM, López-Otín C (1999) Evaluation of some newer matrix metalloproteinases. Ann NY Acad Sci 878:25–39PubMedCrossRef

Delassus GS, Cho H, Hoang S, Eliceiri GL (2010) Many new down- and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers. J Cell Physiol 224:549–558PubMedCrossRef

Delassus GS, Cho H, Eliceiri GL (2011) New signaling pathways from cancer progression modulators to mRNA expression of matrix metalloproteinases in breast cancer cells. J Cell Physiol 226:3378–3384PubMedCrossRef

Sampieri CL, Nuttall RK, Young DA, Goldspink D, Clark IM, Edwards DR (2008) Activation of p38 and JNK MAPK pathways abrogates requirement for new protein synthesis for phorbol ester mediated induction of select MMP and TIMP genes. Matrix Biol 27:128–138PubMedCrossRef

Weng CJ, Chen MK, Lin CW, Chung TT, Yang SF (2011) Single nucleotide polymorphisms and haplotypes of MMP-14 are associated with the risk and pathological development of oral cancer. Ann Surg Oncol (in press)

10.

Chen TY, Li YC, Liu YF, Tsai CM, Hsieh YH, Lin CW, Yang SF, Weng CJ (2011) Role of MMP14 gene polymorphisms in susceptibility and pathological development to hepatocellular carcinoma. Ann Surg Oncol 18:2348–2356PubMedCrossRef

11.

Kondratiev S, Gnepp DR, Yakirevich E, Sabo E, Annino DJ, Rebeiz E, Laver NV (2008) Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas. Hum Pathol 39:337–343PubMedCrossRef

12.

Zarrabi K, Dufour A, Li J, Kuscu C, Pulkoski-Gross A, Zhi J, Hu Y, Sampson NS, Zucker S, Cao J (2011) Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem 286:33167–33177PubMedCrossRef

13.

Xie H, Xue YX, Liu LB, Wang P, Liu YH, Ying HQ (2011) Expressions of matrix metalloproteinase-7 and matrix metalloproteinase-14 associated with the activation of extracellular signal-regulated kinase1/2 in human brain gliomas of different pathological grades. Med Oncol 28(1):S433–S438

14.

Sun L, Yan W, Wang Y, Sun G, Luo H, Zhang J, Wang X, You Y, Yang Z, Liu N (2011) MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. Brain Res 1389:9–18PubMedCrossRef

15.

Pendás AM, Folgueras AR, Llano E, Caterina J, Frerard F, Rodríguez F, Astudillo A, Noel A, Birkedal-Hansen H, López-Otín C (2004) Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol Cell Biol 24:5304–5313PubMedCrossRef

16.

Beck IM, Rückert R, Brandt K, Mueller MS, Sadowski T, Brauer R, Schirmacher P, Mentlein R, Sedlacek R (2008) MMP19 is essential for T cell development and T cell-mediated cutaneous immune responses. PLoS One 3:e2343PubMedCrossRef

17.

Zhao S, Zhao Y, Niu P, Wang N, Tang Z, Zan L, Li K (2011) Molecular characterization of porcine MMP19 and MMP23B genes and its association with immune traits. Int J Biol Sci 7:1101–1113PubMedCrossRef

18.

Chan KC, Ko JM, Lung HL, Sedlacek R, Zhang ZF, Luo DZ, Feng ZB, Chen S, Chen H, Chan KW, Tsao SW, Chua DT, Zabarovsky ER, Stanbridge EJ, Lung ML (2011) Catalytic activity of matrix metalloproteinase-19 is essential for tumor suppressor and anti-angiogenic activities in nasopharyngeal carcinoma. Int J Cancer 129:1826–1837

19.

Delassus GS, Cho H, Park J, Eliceiri GL (2008) New pathway links from cancer-progression determinants to gene expression of matrix metalloproteinases in breast cancer cells. J Cell Physiol 17:739–744CrossRef

20.

Lai K, Conway RM, Crouch R, Jager MJ, Madigan MC (2008) Expression and distribution of MMPs and TIMPs in human uveal melanoma. Exp Eye Res 86:936–941PubMedCrossRef

21.

Müller M, Beck IM, Gadesmann J, Karschuk N, Paschen A, Proksch E, Djonov V, Reiss K, Sedlacek R (2010) MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells. Mod Pathol 23:511–521PubMedCrossRef

22.

Jackson V, Olsson T, Kurtovic S, Folkersen L, Paloschi V, W?gs?ter D, Franco-Cereceda A, Eriksson P. (2011) Matrix metalloproteinase 14 and 19 expression is associated with thoracic aortic aneurysms. J Thorac Cardiovasc Surg. In press

23.

Velinov N, Aebersold D, Haeni N, Hlushchuk R, Mishev G, Weinstein F, Sedlacek R, Djonov V (2007) Matrix metalloproteinase-19 is a predictive marker for tumor invasiveness in patients with oropharyngeal squamous cell carcinoma. Int J Biol Markers 22:265–273PubMed

24.

Jost M, Folgueras AR, Frérart F, Pendas AM, Blacher S, Houard X, Berndt S, Munaut C, Cataldo D, Alvarez J, Melen-Lamalle L, Foidart JM, López-Otín C, Noël A (2006) Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res 66:5234–5241PubMedCrossRef

25.

Stojic J, Hagemann C, Haas S, Herbold C, Kühnel S, Gerngras S, Roggendorf W, Roosen K, Vince GH (2008) Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res 60:40–49PubMedCrossRef

26.

Lettau I, Hattermann K, Held-Feindt J, Brauer R, Sedlacek R, Mentlein R (2010) Matrix metalloproteinase-19 is highly expressed in astroglial tumors and promotes invasion of glioma cells. J Neuropathol Exp Neurol 69:215–223PubMedCrossRef

Title: Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma
Authors: Liang Wang
Jun Yuan
Yanyang Tu
Xinggang Mao
Shiming He
Guoqiang Fu
Jianhai Zong
Yongsheng Zhang
Publication date: 01-02-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 2/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0900-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2013

Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma

MYC oncogene in myeloid neoplasias

Ultrasound-assisted endocavitary HDR-Ir192 brachytherapy for unresectable locally advanced uterine cervix carcinoma: retrospective analysis focusing the efficacy and tolerability

The role of annexin A3 playing in cancers

Human adipose tissue from normal and tumoral breast regulates the behavior of mammary epithelial cells

Multicenter validation of two nomograms to predict non-sentinel node involvement in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer